InnovAge Holding Corp. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2023. Unaudited consolidated financial statements. InnovAge operates PACE programs serving seniors; at period-end it served approximately 6,780 participants across 18 centers in five states.
Financial performance
Amounts are in millions, except per-share data and percentages.
| Metric | Three months ended Dec. 31, 2023 | Year-over-year change | Six months ended Dec. 31, 2023 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $188.9 | +12.8% | $371.4 | +9.7% |
| Operating loss | $(1.8) | Prior-year loss $(13.7) | $(12.5) | Prior-year loss $(30.3) |
| Net loss | $(3.8) | Prior-year loss $(10.5) | $(14.8) | Prior-year loss $(24.2) |
| Net loss attributable to InnovAge | $(3.4); $(0.03) per share | Prior-year $(9.8); $(0.07) per share | $(13.8); $(0.10) per share | Prior-year $(22.9); $(0.17) per share |
| Adjusted EBITDA (non-GAAP) | $7.8 | Prior-year $(2.0) | $10.0 | Prior-year $(5.8) |
For the six months, center-level contribution margin was $61.5 million, or 16.6% of revenue, compared with $44.0 million, or 13.0%, a year earlier. GAAP net loss margin improved to 4.0% from 7.2% (losses as a percentage of revenue). Adjusted EBITDA margin was 2.7%, versus negative 1.7%. Adjusted EBITDA is a non-GAAP measure and includes adjustments such as stock compensation, litigation, business optimization, EMR implementation and an investment impairment.
Balance sheet, cash flow and debt
- At December 31, cash and cash equivalents were $54.1 million, short-term investments $44.7 million, and current assets $157.0 million. Cash plus short-term investments totaled $98.8 million.
- Cash and cash equivalents declined $73.2 million from June 30. Six-month operating cash use was $42.3 million, investing cash use $26.3 million and financing cash use $4.6 million.
- Accounts receivable increased to $43.5 million from $24.3 million at June 30; management cited timing of Medicaid receipts. The cash-flow statement also reflects a $28.1 million reduction in deferred revenue.
- Debt principal totaled $67.9 million, including $65.6 million under the term loan and $2.3 million under a convertible loan. The term-loan rate was 7.30%. The company reported no revolver borrowings and $96.9 million of remaining capacity, and said it was in compliance with credit-agreement covenants.
- Operating and finance lease liabilities totaled $45.5 million. Management believes available liquidity and financing sources can fund needs for the next 12 months and beyond, while cautioning that estimates depend on assumptions.
Material changes and business developments
- Revenue growth reflected higher capitation rates and increased participant months. For the six-month period, capitation rates rose 8.4% and member months rose 1.2%; census was approximately 6,780 versus 6,460 a year earlier.
- Higher external provider costs and care-delivery costs partly offset revenue growth. For six months, external provider costs increased 5.6% and cost of care excluding depreciation and amortization increased 4.4%, driven by provider rates, utilization, wages, staffing and transportation.
- Corporate, general and administrative expense fell 8.1% for six months, primarily due to lower legal, consulting, insurance, contract-staffing and recruiting costs. Sales and marketing expense rose 37.3% as enrollment activity increased following release of prior sanctions.
- On December 1, 2023, InnovAge acquired two California PACE programs from ConcertoCare for $23.9 million in cash. One was operating at acquisition; the Bakersfield program was still pursuing licensure. Results were not significant in the reported period, and the purchase-price allocation remained preliminary.
- A $1.9 million impairment was recorded for the Jetdoc minority investment. The filing says impairment indicators were identified after period-end but determined to exist at December 31.
Outlook, commentary and key risks
- The filing provides no specific numerical financial guidance. Management expects elevated operating expenses for the remainder of fiscal 2024 and continued investment in remediation, growth, new centers and the EMR system.
- Management cited wage and labor-market pressure, rising medical and provider costs, and risks from Medicaid eligibility-redetermination delays. It said the eligibility delays had not materially affected results to date, but can temporarily halt Medicaid revenue and increase recovery risk.
- Regulatory oversight remains a major uncertainty. Following a Sacramento audit, CMS approved the company’s corrective action plan in January 2024. DHCS subsequently reported deficiencies at Sacramento and announced a medical review of San Bernardino. DHCS suspended state attestations for planned Downey and Bakersfield centers pending remediation and review.
- The company continues to cooperate with Colorado and federal Department of Justice civil investigative demands concerning billing, services, referrals, audits and care quality. Outcomes are not predictable. A securities class action proceeded to discovery after a motion to dismiss was granted in part and denied in part; a related derivative case was stayed. A California wage-and-hour settlement was increased to $1.3 million and remained subject to court approval.
- Pennsylvania nurses and certified nurse assistants voted to unionize, representing about 1% of the workforce; collective bargaining had not commenced. The filing’s risk-factor section gives an election date of December 6, 2024, while its MD&A states December 6, 2023. This internal date discrepancy should be checked against the filed document.
- Other key risks include the fully capitated model’s exposure to medical costs, dependence on Medicare and Medicaid, audit and remediation outcomes, participant growth and retention, and the ability to obtain approvals for new centers. Management reported disclosure controls were effective at period-end.
Important facts for investors to verify
- Current status and potential consequences of Sacramento deficiencies, the San Bernardino medical review, and suspended California center attestations.
- Cash conversion and Medicaid receivable collection, including whether operating cash use and the deferred-revenue decline are temporary or recurring.
- Concerto program licensing, integration, participant growth and the final purchase-price allocation.
- Progress in remediation and any new findings, enforcement actions or outcomes of the government investigations and litigation.
- Whether revenue and enrollment growth can outpace medical-cost, wage and provider-cost inflation, and whether management issues formal guidance.